News
CLL combo treatment: Phase-3 study inconclusive
Results of the clinical trial of a CLL drug triplet therapy, presented at ASCO 2023, showed that more data are needed to determine its long-term...
News
New CLL meds: Improved survival rates, 1990-2018
A just-published retrospective study shows nearly 30 years of steady progress in lengthening the lives of U.S. adults with CLL and other leukemias...
News
DLBCL: Major new treatment breakthroughs
After decades of slow progress, new drugs and therapies are paving the way to more effective treatment of DLBCL.
News
Experts debate reducing ASCT for multiple myeloma
Overall survival following multidrug regimens and transplant are on par, raising questions about the best frontline therapy for multiple myeloma...
News
Frontline CLL treatment: Avoiding adverse events
Single-agent frontline therapy helps patients with CLL live longer, but those at high risk of relapse may benefit from multiagent treatment.
News
Relapsed CLL: New approaches prolong survival
Venetoclax, with a second-generation generation Bruton’s tyrosine kinase inhibitor, can lead patients with relapsed CLL back to remission.
News
MRD: Powerful metric for CLL research
New study showed how leukemia specialists can harness measurable residual disease to gauge the efficacy of novel treatment options.
News
SCD meds: Why such ‘slow uptake’?
A nationwide study found that pain medications approved to treat sickle cell disease were prescribed to fewer than one in three patients with SCD...
News
Black women have higher state-level rates of TNBC
The state-level disparities highlight gaps in physicians’ understanding of how social factors contribute to disparities in TNBC risk.
News
Zika virus still calls for preparedness and vaccine development
“There’s no antiviral that you can take for Zika. Until we have a vaccine, the key to controlling/preventing Zika is controlling the mosquitoes...
News
Radiotherapy for early breast cancer: Sharp cutoff at age 70
Radiation therapy was 50% less likely to be prescribed for patients age 70 and older with early-stage breast cancer.
News
Maintenance therapies boost MM survival rates
Interim results in the phase 3 ATLAS trial seemed to buttress the benefits of intensive maintenance therapies for multiple myeloma, post...
News
Systematic review supports preferred drugs for HIV in youths
Findings support the use of dolutegravir an raltegravir as part of WHO-recommended regimens for treating HIV.
News
Exciting advances in HR-positive breast cancer: Top five picks from SABCS
Treatments meet unmet need and address unanswered questions.
News
Key research on TNBC: Top five picks from SABCS
A study on the impact of platinum therapy on long-term TNBC outcomes ranks among the most popular.